James (Jim) H. Welch has been appointed CFO of Cognoa. Welch will oversee financial planning, operations and investor relations as the company advances its digital therapeutics and digital medicines towards commercialization in 2020. Welch has an impressive 20-year track record of success guiding emerging biotech companies—managing two IPOs, as well as raising a combined total of $800M in support of research, development, and preparation for commercialization. “We are delighted to have Jim join the Cognoa leadership team. Jim’s experience and expertise scaling high-growth biotech companies make him the ideal CFO for Cognoa as we look to gain FDA clearance and commercialize our pipeline of prescription digital therapeutics,” said Brent Vaughan, co-founder, and CEO of Cognoa.
James (Jim) H. Welch has been appointed CFO of Cognoa. Welch will oversee financial planning, operations and investor relations as the company advances its digital therapeutics and digital medicines towards commercialization in 2020. Welch has an impressive 20-year track record of success guiding emerging biotech companies—managing two IPOs, as well as raising a combined total of $800M in support of research, development, and preparation for commercialization. “We are delighted to have Jim join the Cognoa leadership team. Jim’s experience and expertise scaling high-growth biotech companies make him the ideal CFO for Cognoa as we look to gain FDA clearance and commercialize our pipeline of prescription digital therapeutics,” said Brent Vaughan, co-founder, and CEO of Cognoa.